Discover a new low-dose, inexpensive, at-home treatment for depression that is revolutionizing the treatment of ...
The FDA has requested new human factors and pharmacology studies for Anaphylm sublingual film following deficiencies in original NDA packaging data.
More than 15 years ago, Yale's Gail D'Onofrio started studying the effectiveness of sublingual (under-the-tongue) buprenorphine for treatment of opioid use disorder (OUD) in the emergency department.
New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and ...
The United States Food and Drug Administration recently approved Tonmya TM (cyclobenzaprine hydrochloride sublingual tablets) ...
H1 2026: Finalize formulation and manufacture test product. H1 2026 Initial Phase 1 pharmacokinetic clinical cross-over study. "Our pipeline is focused on research in therapeutic areas where we can ...
Researchers have found in a new study that given its natural origin, Wheatgrass (WG) may be a promising adjunct or ...
H2 2025: Request meeting with FDA to discuss 505(b)(2) pathway. H2 2025: Target submission of New Drug Application (NDA). Sublingual ED medication H1 2026: Finalize formulation and manufacture test ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results